• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, August 3, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Immunology

Viral hepatitis: Europe needs to close the testing gap

Bioengineer by Bioengineer
July 27, 2020
in Immunology
Reading Time: 4 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

World Hepatitis Day: is Europe on track for the on the way towards the Sustainable Development Goal for health

IMAGE

Credit: ECDC

Approximately four in five people living with hepatitis B and three out of four people with hepatitis C infection across the European Union and European Economic Area (EU/EEA) and the UK have not yet been diagnosed. This is a major obstacle on the way towards the Sustainable Development Goal (SDG) for health in 2030 as highlighted by ECDC on occasion of World Hepatitis Day.

ECDC is working in close collaboration with the World Health Organization to monitor the progress towards the elimination of hepatitis B (HBV) and C (HCV) across the EU/EEA. The first progress report highlights major gaps in prevention programmes in the region with suboptimal HBV vaccination coverage and insufficient levels of harm reduction targeting people who inject drugs.

The report shows that robust data for the so-called continuum of care looking at the numbers of diagnosed people and those in treatment and care are lacking in most countries. However, available data suggest that a high proportion of people living with hepatitis B and C infections appear to be undiagnosed and that many of those who have been diagnosed with hepatitis B and C infection are not receiving life-saving treatment. Available evidence also indicates that those at high risk of infection, including people who inject drugs and people in prison, are not being effectively targeted for testing.

In addition, mortality related to viral hepatitis is high across the region and there is very little evidence of progress towards the 2030 elimination target of a 65% reduction in mortality against the 2015 baseline.

“Looking at the latest monitoring results and surveillance data in 2020, we have to conclude that we are not on track to reach the 2030 target. To get there, Europe needs to massively scale up efforts to reduce the number of people who have never been tested for hepatitis B and C, especially among people at most risk of infection”, highlights ECDC Director Andrea Ammon on occasion of World Hepatitis Day on 28 July. “Safe and effective vaccines are the main pillar for hepatitis B prevention. In addition, effective hepatitis treatment exists and improves the health of those who receive it. Treatment also helps preventing further transmission. It is as simple as that: people need to know their hepatitis status if we are to make progress towards eliminating these diseases by 2030.”

European surveillance data show on-going transmission of hepatitis B and, despite a recent slight decline, high annual levels of hepatitis C diagnoses.

But according to recent ECDC findings, only a few countries across the EU/EEA have met the 2020 target of the European Action Plan to diagnose 50% of people with chronic hepatitis.

The ECDC testing guidance provides an overview of effective strategies to identify those with undiagnosed infection and highlights the importance of community testing and the integration of testing services (e.g. HIV and hepatitis) to enable synergies and efficiency in times of resource constraints.

Early diagnosis and linkage to care bring strong individual and public health benefits: effective viral hepatitis treatment either eliminates or suppresses the viruses significantly which in turn means that those on treatment interrupt existing transmission chains, preventing further infections.

The European Test Finder makes it easy to locate testing sites for HIV, hepatitis and sexually transmitted infections across Europe.

###

Read the full report

Monitoring the responses to hepatitis B and C epidemics in the EU/EEA Member States, 2019

https://www.ecdc.europa.eu/en/world-hepatitis-day-2020

Related content

Annual Epidemiological Report for 2018 – hepatitis B

https://www.ecdc.europa.eu/en/publications-data/hepatitis-b-annual-epidemiological-report-2018

Annual Epidemiological Report for 2018 – hepatitis C

https://www.ecdc.europa.eu/en/publications-data/hepatitis-c-annual-epidemiological-report-2018

Public health guidance on HIV, hepatitis B and C testing in the EU/EEA

https://www.ecdc.europa.eu/en/publications-data/public-health-guidance-hiv-hepatitis-b-and-c-testing-eueea

Hepatitis B and C testing activities, needs, and priorities in the EU/EEA

https://ecdc.europa.eu/en/publications-data/hepatitis-b-and-c-testing-activities-needs-and-priorities-eueea

Mortality from liver diseases attributable to hepatitis B and C in the EU/EEA – descriptive analysis and estimation of 2015 baseline

https://www.tandfonline.com/doi/full/10.1080/23744235.2020.1766104

Media Contact
ECDC press office
[email protected]

Original Source

https://www.ecdc.europa.eu/en/news-events/viral-hepatitis-europe-needs-close-testing-gap

Tags: Eating Disorders/ObesityEpidemiologyHealth CareHealth Care Systems/ServicesHealth ProfessionalsInfectious/Emerging DiseasesLiverMedicine/HealthPublic HealthSex-Linked Conditions
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

UMass Amherst grad student awarded fellowship for food allergy research

July 23, 2021
IMAGE

Less-sensitive COVID-19 tests may still achieve optimal results if enough people tested

July 22, 2021

Public trust in CDC, FDA, and Fauci holds steady, survey shows

July 20, 2021

USC study shows male-female differences in immune cell function

July 19, 2021
Please login to join discussion

POPULAR NEWS

  • Blind to the Burn

    Overlooked Dangers: Debunking Common Myths About Skin Cancer Risk in the U.S.

    60 shares
    Share 24 Tweet 15
  • Neuropsychiatric Risks Linked to COVID-19 Revealed

    49 shares
    Share 20 Tweet 12
  • Dr. Miriam Merad Honored with French Knighthood for Groundbreaking Contributions to Science and Medicine

    46 shares
    Share 18 Tweet 12
  • Study Reveals Beta-HPV Directly Causes Skin Cancer in Immunocompromised Individuals

    38 shares
    Share 15 Tweet 10

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Predicting Colorectal Cancer Using Lifestyle Factors

Optical Matrix Multipliers Revolutionize Image Encoding and Decoding

Voltage Imaging Uncovers Hippocampal Memory Inhibition Dynamics

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.